MINERALYS THERAPEUTICS, INC. Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities
MINERALYS THERAPEUTICS, INC. (MLYS) reported Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities of $627.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities · last filed 2026-08-11
- MINERALYS THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of held-to-maturity securities for the quarter ending 2026-06-30 was $325.00M, a 333.33% increase year-over-year.
- MINERALYS THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of held-to-maturity securities for the quarter ending 2026-03-31 was $302.50M, a 764.29% increase year-over-year.
- MINERALYS THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of held-to-maturity securities for the quarter ending 2025-12-31 was $165.00M, a 11.86% increase year-over-year.
- MINERALYS THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of held-to-maturity securities for the quarter ending 2025-09-30 was $150.00M, a 8.30% increase year-over-year.
- MINERALYS THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of held-to-maturity securities for fiscal 2025 was $425.00M, a 13.00% decline from fiscal 2024.
- MINERALYS THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of held-to-maturity securities for fiscal 2024 was $488.50M, a 160.53% increase from fiscal 2023.
- MINERALYS THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of held-to-maturity securities for fiscal 2023 was $187.50M, a 275.00% increase from fiscal 2022.
- MINERALYS THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of held-to-maturity securities for fiscal 2022 was $50.00M.
| Period end | Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities 3 month | Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities 6 month | Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities 9 month | Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $325.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $627.50M 10-Q · filed 2026-08-11 | $792.50M derived: sum of 3 quarters · filed 2026-08-11 | $942.50M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $302.50M 10-Q · filed 2026-05-06 | $467.50M derived: sum of 2 quarters · filed 2026-05-06 | $617.50M derived: sum of 3 quarters · filed 2026-05-06 | $692.50M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $165.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $315.00M derived: sum of 2 quarters · filed 2026-03-12 | $390.00M derived: sum of 3 quarters · filed 2026-08-11 | $425.00M 10-K · filed 2026-03-12 |
| 2025-09-30 | $150.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $225.00M derived: sum of 2 quarters · filed 2026-08-11 | $260.00M 10-Q · filed 2025-11-10 | $407.50M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $75.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $110.00M 10-Q · filed 2026-08-11 | $257.50M derived: sum of 3 quarters · filed 2026-08-11 | $396.00M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $35.00M 10-Q · filed 2026-05-06 | $182.50M derived: sum of 2 quarters · filed 2026-05-06 | $321.00M derived: sum of 3 quarters · filed 2026-05-06 | $456.00M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $147.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $286.00M derived: sum of 2 quarters · filed 2026-03-12 | $421.00M derived: sum of 3 quarters · filed 2026-03-12 | $488.50M 10-K · filed 2026-03-12 |
| 2024-09-30 | $138.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $273.50M derived: sum of 2 quarters · filed 2025-11-10 | $341.00M 10-Q · filed 2025-11-10 | $406.00M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $135.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $202.50M 10-Q · filed 2025-08-12 | $267.50M derived: sum of 3 quarters · filed 2025-08-12 | $327.50M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $67.50M 10-Q · filed 2025-05-12 | $132.50M derived: sum of 2 quarters · filed 2025-05-12 | $192.50M derived: sum of 3 quarters · filed 2025-05-12 | $232.50M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $65.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $125.00M derived: sum of 2 quarters · filed 2025-02-12 | $165.00M derived: sum of 3 quarters · filed 2025-02-12 | $187.50M 10-K · filed 2025-02-12 |
| 2023-09-30 | $60.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $100.00M derived: sum of 2 quarters · filed 2024-11-12 | $122.50M 10-Q · filed 2024-11-12 | $172.50M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $40.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $62.50M 10-Q · filed 2024-08-13 | $112.50M derived: sum of 3 quarters · filed 2024-08-13 | $112.50M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $22.50M 10-Q · filed 2024-05-09 | $72.50M derived: sum of 2 quarters · filed 2024-05-09 | $72.50M derived: sum of 3 quarters · filed 2024-05-09 | $72.50M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $50.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $50.00M derived: sum of 2 quarters · filed 2024-03-21 | $50.00M derived: sum of 3 quarters · filed 2024-03-21 | $50.00M 10-K · filed 2024-03-21 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $0.00 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |